Please login to the form below

Not currently logged in
Email:
Password:

Belgium's TiGenix appoints Dr Gregory Gordon

He takes up a role as head of its US medical development

Gregory GordonBelgium biopharma firm TiGenix has appointed Dr Gregory Gordon to head up its US medical department as part of moves to strengthen its stateside operations.

TiGenix has also appointed Annette Valles-Sukkar as associate director, clinical projects, and both she and Dr Gordon will report to the company’s chief medical officer Dr Marie Paule Richard.

Dr Gordon joins TiGenix from Nestlé Health Science, where he was global clinical affairs lead, gastrointestinal health and prior to that he has worked at Stealth BioTherapeutics, Ironwood Pharmaceuticals and Parexel.

Meanwhile, Valles-Sukkar arrives at TiGenix from Alexion Pharmaceuticals, where she was responsible for all aspects of clinical trial development.

Dr Marie Paule Richard said: “We are delighted to welcome Gregory and Annette to TiGenix and to further build the team at our US headquarters in Cambridge, MA.

“Gregory has exceptional experience in drug development generally and specifically with gastrointestinal products. Annette has proven ability to manage large-scale late-stage clinical trials.”

3rd October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics